We previously documented the lowest frequency of CYP2C9*2 in Mexican indigenous Tepehuanos followed by Mestizos and Mexican-Americans populations, suggesting a negative correlation between the CYP2C9*2 frequency and the degree of Asian ancestry in indigenous Americans. We determined the influence of ethnic admixture components on the CYP2C9 allele distribution in 505 Amerindian from eight indigenous populations through genotyping CYP2C9*2, *3 and *6 alleles by real-time PCR and molecular evaluation of ancestry. The frequencies for CYP2C9*2 were 0.026 in Seris and 0.057 in Mayos, being higher than in Asians (Po0.001). CYP2C9*3 was found in Tarahumaras (0.104), Mayos (0.091), Tepehuanos (0.075), Guarijíos (0.067), Huicholes (0.033) and Coras (0.037), with East Asians having lower frequencies than the former three groups (Po0.001). CYP2C9*6 was not found. The frequency of CYP2C9*2 was lower in Amerindians than in European populations, and higher than their Asian ancestors. The presence of this allele in ethnic groups in Mexico can be explained by European admixture.
INTRODUCTION
The cytochrome P450 (CYP) family enzyme system is a primary metabolic pathway for the biotransformation of drugs. CYP genes are highly polymorphic and are known to contribute to interindividual and interethnic variations in the metabolism of a large number of drugs in humans. 1 In human liver, CYP2C9 is the major enzyme of the CYP2C subfamily that is involved in the metabolism of clinically important drugs, including phenytoin, tolbutamide, warfarin and nonsteroidal anti-inflammatory drugs; some of these drugs have a narrow therapeutic index. 2, 3 Presently, 435 different CYP2C9 allelic variants have been described, 4 and CYP2C9*2 (C430T, Arg144Cys, rs1799853) and CYP2C9*3 (A1075C, Ile359Leu, rs1057910) are the most important variants that encode enzymes with reduced enzymatic activity. 5, 6 CYP2C9*2 has about 12% of the wild-type enzyme activity, 7, 8 and has been associated to lower dose requirements for some drugs as warfarin, 9 whereas CYP2C9*3 has less than 5% of such activity and has been found in subjects with slow metabolism for several CYP2C9 drug substrates.
7,10-12 CYP2C9*6 (818delA, 273frameshift, rs9332131) is a less common variant that has been linked to a lower clearance of phenytoin. 13 Mexico has one of the richest ethnic, cultural and linguistic diversities in the American continent. At present, this country has 11 linguistic families divided into 468 linguistic groups. 14 Most of the existing Native Mexican groups have settled in difficult to access areas, and retain their traditional lifestyle and language. As Native Americans are believed to have descended from Asian populations who peopled the New World through the Bering Strait, 15 we could expect that allele frequencies of CYP2C9 variants are similar to those found in some Asian populations. In Asia, the frequency of CYP2C9*2 (0-0.001) and CYP2C9*3 (0.011-0.049) alleles appear at a lower frequencies than in Europeans (0.10-0.16 and 0.052-0.097, respectively). [16] [17] [18] [19] Recently we reported a significant difference in CYP2C9*2 allele prevalence between the Mexican (0.01-0.07) and Spanish populations (0.16) (Po0.05). Mexicans subjects also display differences among indigenous Tepehuanos (0.01), Mexican-Mestizos (0.07) and MexicanAmericans (0.08) (Po0.05). 20 The frequency of CYP2C9*3 was found to be lower (Po0.05) in indigenous Tepehuanos (0.015) and Mexican-Mestizos (0.015) than in Mexican-Americans (0.06) and Spaniards (0.08) (Po0.05), 20 but similar to that found in Asians (0.01-0.05). 21, 22 Therefore, this was assumed to be related to the low frequencies of CYP2C9*2 and *3 in Asians. The CYP2C9*6 allele was reported at a frequency of 0.06 in African-Americans, 13 and at an estimated frequency of o0.01 in Mexican-Mestizos. 20 Little is known about the genetic variation of CYP2C9 in indigenous populations from Mexico, which have both distinctive genetic background and environmental conditions from other studied groups. Therefore, the aim of this study was to determine the allele frequencies of CYP2C9*2, *3 and *6 in eight Native groups from different Northwest Mexico states, and to compare these data with previously reported frequencies of Asian and Native American populations. Additionally, the ancestral components (admixture) were determined in these groups to assess whether the European ancestry is responsible for the presence of CYP2C9*2 in these indigenous groups. Volunteers were included in the study after they were informed of the nature of the study, and signed a consent form.
CYP2C9 genotyping
All biological samples were taken from volunteers at their respective communities. Five milliliters of peripheral blood were drawn in a tube with EDTA, and kept on ice during transportation to the laboratory. Genomic DNA was isolated with the QIAGEN Blood DNA isolation kit (QIAGEN, Hilden, Germany) and evaluated for integrity and concentration through 1% agarose electrophoresis and spectrophotometry. Genotyping was performed by quantitative real-time PCR technology using TaqMan assays and StepOne (Applied Biosystems, Carlsbad, CA, USA) equipment. Polymerase chain reaction amplification for all single-nucleotide polymorphisms was performed in 20 ml final volume with 20 ng of template DNA, 1X TaqMan genotyping Master Mix (Applied Biosystems), 1X-specific TaqMan probe and water. Thermal cycling conditions were as follows: initial denaturation step of 10 min at 95 1C, followed by 40 cycles of denaturation at 92 1C for 15 s and annealing at 60 1C for 1 min. The identification of genotypes was carried out using allelic discrimination software (Applied Biosystems).
Admixture analysis
Population admixture was evaluated through the analysis of 15 short tandem repeats (STRs) loci (D8S1179, D21S11, D7S820, CSF1P0, D3S1358, TH01, D13S317, D16S539, D2S1338, D19S433, VWA, TPOX, D18S51, D5S818 and FGA) using the AmpFISTR identifiler kit (Applied Biosystems) following the manufacture's recommendations. PCR products were analyzed by capillary electrophoresis in an ABI-Prism 3130 genetic analyzer, and genotypes were obtained by comparison with allelic ladders provided with the kit and the GeneMapper software 3.1. (Applied Biosystems).
Statistics
The CYP2C9 allele frequencies were compared with w 2 and Fisher's exact tests. Statistical analysis were carried out using the program Sigma Plot v11 (Systat Software, Chicago, IL, USA). Hardy-Weinberg equilibrium was determined by comparing the genotype frequencies with the expected values using a contingence table X 2 statistic with Yates's correction. A P-value o0.05 was regarded as statistically significant in all cases. Based on the 15 STRs database obtained from each population, the software STRUCTURE was used to estimate ancestral proportions and the number of clusters (K). 23 The replicates of the runs were 50 000-iterations burn-in period for each parameter and for each cluster value from 1-10, and 25 replicates were carried out for a particular K. We used the admixture model and allelic frequencies correlations with a-value separated for population and three populations groups designated as ancestral (supervised analysis). The Amerindian, European and African ancestries were obtained by pooling the population data referred in Table 1 .
RESULTS

CYP2C9 genotyping
The allele frequencies for all populations investigated are summarized in Table 2 . The wild-type allele CYP2C9*1 was uniquely found in the Mexicanero group (1.0), and was the most frequent allele in the Seris (0.974), Huicholes (0.967), Coras (0.963), Guarijíos (0.933) and Tepehuanos (0.925) Native groups. The allele CYP2C9*2 was found only in Seris (0.026) and Mayos (0.057). The highest frequency for CYP2C9*3 was observed in Tarahumaras (0.104) and Mayos (0.091), followed by Tepehuanos (0.075) and Guarijíos (0.067). Conversely, the lowest frequency for CYP2C9*3 was seen in Huicholes (0.033) and Coras (0.037). Differences were noticed between the Tarahumaras and the Huichol and Cora groups (Po0.05). The CYP2C9*6 variant was not detected in any group.
CYP2C9*2 and *3 were in Hardy-Weinberg equilibrium (X 2 P40.05) for all the studied populations, and genotype frequencies are described in Table 3 . We identified only one subject in the Seri group (5.26%) and five subjects in the Mayo group (11.36%) with the heterozygote status CYP2C9*1/*2. However, no single homozygote *2/*2 was detected. The *1/*2 genotype frequency in Mayos was significantly higher than in Huicholes, Coras, Tarahumaras (Po0.01), Tepehuanos (Po0.001) and Mexicaneros (P ¼ 0.023). Among all Mexican population samples, homozigosity for the allele CYP2C9*3 was found only in two Tepehuano subjects (1.57%). The heterozygous genotype *1/*3 was prevalent among Tarahumaras (20.27%), Mayos (18.18%), Guarijíos (13.33%) and Tepehuanos (11.81%) individuals, and it was less frequent in Coras According to CYP2C9*3 allele frequency, we estimated 1.57% of poor metabolizers (*3/*3) in the Tepehuano population, the only Native group that showed *3/*3 homozygotes. Different studies suggest that only individuals homozygous for CYP2C9*3 exhibit the slow metabolizer status, and that individuals with CYP2C9*1/ *3, *2/*2 or *2/*3 genotypes may have only low enzyme activity. 7, 11, 12, 32 Admixture in Mexican Native groups To further characterize these groups, we studied 15 STRs to estimate non-Amerindian ancestry in all the Native American population samples here analyzed (Table 4) . European ancestry was considerably high among Mayos, Guarijíos and Seris (32.60%, 16.80% and 11%, respectively). These results explain the unexpected detection of the CYP2C9*2 allele in the Mayos and Seris groups, which is more prevalent in European and EuroAmerican populations (8-16%). 7, [33] [34] [35] Conversely, the relatively high frequency of CYP2C9*3 allele among these groups does not seem to be evidence for Asian ancestry.
Interpopulation comparisons
The comparison between the studied Amerindian groups and worldwide populations is showed in Figure 1 . The CYP2C9*2 allele frequency in Seris and Mayos subjects was greater than in East Asian populations (Po0.001) and was not different from MexicanMestizos (0.07), Mexican-Tepehuanos (0.01) 20 and Canadian Indian (0.03). 36 On the contrary, CYP2C9*2 frequencies in Seris and Mayos individuals were significantly lower than Spaniards (0.16) (P ¼ 0.017 and P ¼ 0.009, respectively) and Euro-American (0.15) (P ¼ 0.030 and P ¼ 0.017, respectively). 7, 19, 36, 37 The lack of CYP2C9*2 allele in the rest of the Mexican-Amerindian groups is in agreement with the reported absence in Asian populations ( Figure 1) .
The allele frequency of CYP2C9*3 in Huicholes, Coras and Guarijíos subjects was similar to the observed in Asians (0.011-0.05), 7, 21, 22, 36, 41 Mexican-Mestizos (0.015) and MexicanTepehuanos (0.015). 20 The CYP2C9*3 allele frequency in Huicholes (P ¼ 0.006) and Coras (P ¼ 0.023) was different only to that reported for the Spanish (0.08) population and other European countries (P ¼ 0.004 and P ¼ 0.023, respectively). Solely in the Tarahumara group the occurrence of CYP2C9*3 was higher than in previously studied Mexican-Tepehuanos (0.015) and Mexican-Mestizos (0.015) (Po0.009). 20 In these Amerindian groups, we observed a similar CYP2C9*3 frequency to that of the Canadian Indian population (0.060), 36 except for the Tarahumaras who presented higher frequency (Po0.001). Finally, CYP2C9*3 allele frequency in Tarahumaras, Tepehuanos and Mayos was higher than in East Asian and African-American populations (Po0.001).
7,37
DISCUSSION
This study was undertaken in eight Native American groups from Northwest Mexico in whom CYP2C9*2, *3 and *6 allele frequencies were determined. Genetic data were compared with worldwide reports, particularly with Asians who presumably gave rise to Native American populations. According to this hypothesis, we would expect to find CYP2C9 allele frequencies in Native groups similar to those of Asian populations, and different from those of Europeans. CYP2C9*2 and *3 allele frequencies had already been reported to be lower in MexicanAmerindians (Tepehuanos) and Mexican-Mestizos, than in Mexican-Americans and Spaniards from Extremadura (Po0.05). 20 In the present study, CYP2C9*2 was not detected in six out of the eight Amerindian groups analyzed, consistent with previous reports in the majority of Asian populations. 7, 41 However, this variant was identified in Mayos (0.057) and Seris (0.026) from Sonora state at a significantly higher frequency compared with that of Asians (Po0.001).
We determined the ancestry in these Mexican Native groups using 15 STRs markers. This analysis confirmed that Native groups conserve Amerindian alleles, in agreement with previous studies including Mexican Native communities. [42] [43] [44] [45] However, the Mayos, Seris and Guarijíos showed higher European admixture 46, 47 A similar observation has been reported for Canadian Native Indian populations, where CYP2C9*2 was found at a frequency of 0.03, but increased to 0.08 and 0.13 in the same group with higher European admixture. 36 On the other hand CYP2C9*2 allele was not detected in a geographically isolated Canadian Inuit group (Eskimo-Aleuts), 36 probably because CYP2C9*2 allele was introduced into the Amerindian groups during the European conquest and settlement.
In the case of CYP2C9*3, the allele frequency fluctuates over a range of 0.033-0.104 in the Mexican Native groups studied, similar to that reported in Europeans 0.033-0.098, but higher than in Asians (0.011-0.068) and African-Americans (0.005-0.023). 35, 37, 39, 48 Previous reports have described the allele CYP2C9*3 in populations of different ethnic origin so, we expected to find this variant in the Amerindian groups analyzed in the present study. However, unlike their Asian ancestors, it is possible that in Mexican-Amerindian populations, the allele frequency of CYP2C9*3 has increased because of environmental factors that could have imposed natural selective pressure or selective advantage for the CYP2C9 activity. 49 This hypothesis needs to be properly addressed in additional studies.
In a previous study by our group, 50 we did not find CYP2D6 poor metabolizers in Tepehuan individuals; however, the present study allows inferring a relatively high frequency of CYP2C9 slow metabolizers (*3/*3) in the same group. To our knowledge this is the highest frequency reported to date. The *3/*3 genotype frequency is associated with significant alterations in the metabolism of CYP2C9 substrates, such as warfarin, phenytoin, losartan and cyclophosphamide. [51] [52] [53] Thus, the relatively high allele frequency of CYP2C9*3 in Amerindian populations has clinical importance. 33, 54 This variant cause the largest reduction in metabolic activity of CYP2C9 substrates when compared with the wild-type allele *1, 55 whereas CYP2C9*2 allele causes a lesser decrement of enzymatic activity. The aforementioned should be taken into account in the individualization of therapeutic regimens and the assessment of adverse reactions for drugs primarily metabolized by CYP2C9, such as anticoagulant, antiepileptic and nonsteroidal antiinflammatory drugs.
Recent technological advances have allowed the development of genome-wide association studies to map genetic variants associated with various phenotypes. 56 However, these studies are partially useful, owing to difficulties in describing human phenotypes accurately and unequivocally. In order to overcome such difficulties, it has been proposed the analysis of extended phenotypes or deep phenotyping based on the large number of features available to describe an individual. 57 On a population level, deep phenotyping is described as systems epidemiology, which integrates various population-level omic-metrics, including Metabolome, Proteome, Transcriptome, Genome and environmental factors, together with the evaluation of their complex interactions. 58 Systems epidemiology may provide a novel approach to study the human pathophysiology and to identify new trans-omic biomarkers for diagnosis and monitoring. 59 In context of pharmacogenomics, systems epidemiology is an opportunity to enhance our understanding of genotypephenotype associations, in order to predict more accurately drug response and support an individualized medicine based on a multiscale analytical approach.
In conclusion, CYP2C9*2 allele frequency was lower in Native American groups than in European populations, and different to their Asian ancestors. The presence of this allele in ethnic groups in Mexico can be explained by European admixture. This should be considered when prescribing drugs for Amerindian populations. Figure 1 . CYP2C9 allele frequencies distribution from different ethnic populations. 7, 19, 20, 34, [36] [37] [38] [39] [40] CYP2C9 among indigenous Mexicans Sosa-Macías M et al
